Latest News & Features
Americas
Apexigen uses antibodies derived from rabbits to develop therapies for diseases that are difficult to treat. LSIPR found out how it protects its novel technologies. 28 February 2014
Europe
Recent CJEU decisions on SPCs have brought little clarity to the meaning of ‘product’, and a recent Advocate General opinion in Bayer CropScience AG threatens to muddy the waters even further, says Paul England. 28 February 2014
Asia
Bayer has announced that it plans to acquire Dihon Pharmaceutical Group, a Chinese company that makes over-the-counter (OTC) and herbal traditional Chinese medicine (TCM) products. 27 February 2014
Americas
The US District Court for the District of Maryland has ruled that Taiwanese company TWi Pharmaceuticals’ generic version of Par Pharmaceuticals’ Megace ES drug does not infringe US patent 7,101,576. 25 February 2014
Americas
Bayer will acquire Norwegian pharmaceutical company Algeta for €2.1 billion ($2.9 million), it announced on Monday. 24 February 2014
Americas
Actavis has announced another expansion with the $25 billion acquisition of US pharmaceutical company Forest Laboratories. 21 February 2014
Big Pharma
Several of the world’s 10 top-selling drugs lose exclusivity this year. LSIPR takes a look at the products, their major competitors, and their manufacturers’ strategies for keeping a grasp of market share. 19 February 2014
Big Pharma
Common themes, in particular in the context of second medical use claims and dosage regimes, are on the radar of the UK courts, as Jennifer Antcliff and Dennis Waller report. 19 February 2014
Big Pharma
The CJEU has delivered its judgment in three SPC cases, in an attempt to address fundamental issues in the SPC Regulation, as well as uncertainties arising from earlier rulings. Although questions have been answered, others have been raised, say David Carling and Michael Pears. 19 February 2014
Asia
The Indian Supreme Court has failed to provide the clarity which is craved by practitioners in its latest pronouncement on the controversial Section 3(d), says Jitesh Kumar. 19 February 2014